An FDA analysis of the association of tumor growth rate and overall and progression-free survival in metastatic non-small cell lung cancer (NSCLC) patients.

Authors

null

Yutao Gong

U.S. Food and Drug Administration, Silver Spring, MD

Yutao Gong , Jeremy Mason , Yuan-Li Shen , Elaine Chang , Dickran Kazandjian , Gideon Michael Blumenthal , Harpreet Singh , Marc Robert Theoret , Shenghui Tang , Richard Pazdur , Julia A. Beaver

Organizations

U.S. Food and Drug Administration, Silver Spring, MD, University of Southern California, Los Angeles, CA, US Food and Drug Administration, Silver Spring, MD

Research Funding

No funding received
None

Background: Previous studies have suggested that tumor growth rate (g), estimated using prostate-specific antigen values, is associated with overall survival (OS) in prostate cancer (Wilkerson, 2016). We performed a retrospective pooled analysis in non-small cell lung cancer (NSCLC) to investigate the extent to which g values estimated using radiological tumor measurements in clinical trials are associated with survival. Methods: We identified 24 randomized clinical trials submitted to FDA between 2013 and 2019 investigating either immune checkpoint inhibitor (ICI) or targeted therapy (TT) in pts with metastatic NSCLC. Of 9934 patients (pts) enrolled, 5532 pts (2401, 1189, and 1942 pts treated with ICI, TT, and chemotherapy respectively) had sufficient data to derive a valid g. The g was evaluated by both type and line of therapy. Pts were then grouped according to quartiles of g, with Q1 being the lowest. We calculated OS and progression-free survival (PFS) for each group via the Kaplan-Meier method, and used the Cox model for group comparison. Results: Median g was 9.7E-4, 1.4E-3, and 2.2E-3/day, and median OS was 34.2, 21.3, and 15.3 months (mo), in pts treated with TT, ICI, and chemotherapy, respectively, regardless of lines of therapy. When treated with the same type of therapy, pts receiving 2nd line therapy had a higher median g than those receiving 1st line. The median survival and log-rank hazard ratios for pts treated with 1st line ICI monotherapy are shown in the Table. Conclusions: TT is associated with the lowest median g, followed by ICI, and then chemotherapy, perhaps due to patient selection, better inherent biology/natural history, or favorable results of TT on selected tumors. Regardless, we found that g is inversely associated with survival, across treatment types. This relationship is also observed in pts treated with the same type and line of therapy (for example, 1st line ICI), where Q1 has the longest survival, followed by Q2, Q3, and then Q4. In summary, our exploratory analysis suggests that g derived from radiological tumor measurements in NSCLC may relate to survival. Prospective studies are needed to evaluate if g might be an earlier endpoint compared to classical response criteria.

NOS
PFS
Median (mo)Hazard RatioMedian (mo)Hazard Ratio
Q1110NR (NR, NR)132.5 (21.5, NR)1
Q210926.1 (22.9, NR)1.8 (1.1, 3.1)13.1 (10.4, 18.7)2.3 (1.6, 3.4)
Q310916.7 (13.5, 22.4)4.6 (2.8, 7.3)6.1 (4.2, 7.1)6.6 (4.5, 9.8)
Q41098.7 (7.2, 12.9)6.8 (4.3, 10.7)3.4 (2.1, 4.1)11.0 (7.2, 16.9)

*NR = Not Reached

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9541)

DOI

10.1200/JCO.2020.38.15_suppl.9541

Abstract #

9541

Poster Bd #

307

Abstract Disclosures